Pharmacokinetic Study on Raltegravir and Lamotrigine - Full Text View

Sponsor:	Radboud University
Collaborator:	Merck
Information provided by:	Radboud University
ClinicalTrials.gov Identifier:	NCT00618241

Purpose

The purpose of this study is to determine whether interactions between raltegravir and lamotrigine take place and to study the safety of the combination raltegravir/lamotrigine before used in HIV patients.

Condition	Intervention	Phase
HIV Infection	Drug: lamotrigine Drug: Raltegravir	Phase I

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	The Influence of Raltegravir (MK-0518) on the Pharmacokinetics of Single-dose Lamotrigine in Healthy Male Subjects (GRANOLA)

Resource links provided by NLM:

Genetics Home Reference related topics: complement factor I deficiency

MedlinePlus related topics: Drug Reactions HIV/AIDS

Drug Information available for: Lamotrigine Raltegravir Raltegravir potassium

U.S. FDA Resources

Further study details as provided by Radboud University:

Primary Outcome Measures:

Plasma concentrations of lamotrigine, lamotrigine-2N-glucuronide, and raltregravir [ Time Frame: just before dosing, at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 24 hours and 48 hours after dosing on study days 4-5 and 32-33. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Determination of pharmacokinetic parameters (AUC, Cmax, Tmax, Cmin and T 1/2) by noncompartmental analysis [ Time Frame: at each sampling time ] [ Designated as safety issue: No ]

Enrollment:	24
Study Start Date:	February 2008
Study Completion Date:	October 2008
Primary Completion Date:	October 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: A Group A: day 1-5 Raltegravir 400 mg oral BD (twice daily). Lamotrigine one oral dose 100 mg on day 4. Wash-out 6-31. Followed by one oral dose Lamotrigine 100 mg on day 34. 5 days Raltegravir 400 mg oral BD. Lamotrigine one oral dose 100mg on day 34.	Drug: lamotrigine 100 mg Other Name: Lamictal Drug: Raltegravir 400 mg BD
Active Comparator: B Group B: day 4 Lamotrigine one oral dose on day 4. Wash-out day 6-28 followed by Raltegravir 400 mg oral BD day 29-33. One dose Lamotrigine 100 mg oral on day 32. One dose Lamotrigine 100 mg oral.	Drug: lamotrigine 100 mg Other Name: Lamictal Drug: Raltegravir 400 mg BD

Detailed Description:

Lamotrigine is an anticonvulsive drug that is used both for the treatment of HIV-associated neuropathic pain and the treatment of epilepsy in HIV-infected individuals. Lamotrigine is metabolized via glucuronidation.

Raltegravir is a newly developed integrase inhibitor that is also metabolized via glucuronidation.

Since both agents are metabolized via glucuronidation, there is a possibility of competition for glucuronidation, leading to drug-drug interactions between raltegravir and lamotrigine.

This primary objective of this study is to determine the effect of raltegravir on the pharmacokinetics of single dose lamotrigine (by intrasubject comparison). A secondary objective is to determine the effect of single dose lamotrigine on the pharmacokinetics of raltegravir when compared to historical controls. Another secondary objective is to evaluate the safety of combined use of single dose lamotrigine and raltegravir.

Eligibility

Ages Eligible for Study:	18 Years to 55 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Between 18 and 55 years of age
Subject does not smoke more than 10 cigarettes, 2 cigars or 2 pipes per day
Subject has a Quetelet Index of 18 to 30 kg/m2
Subject is able and willing to sign informed consent
Subject is in good age-appropriate health condition
Subject has a normal blood pressure and pulse rate

Exclusion Criteria:

History of sensitivity/idiosyncrasy to medicinal products or excipients
Positive HIV test
Positive hepatitis B or C test
Therapy with any drug (2 weeks preceding dosing) except for paracetamol
Relevant history or presence of pulmonary disorders, cardiovascular
History of or current abuse of drugs, alcohol or solvents
Inability to understand the nature and extent of the trial and procedures
Participation in a drug trial within 60 days prior to the first dose
Donation of blood within 60 days prior to the first dose
Febrile illness within 3 days before the first dose

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00618241

Locations

Netherlands
Radboud University Medical Center
Nijmegen, Gelderland, Netherlands

Sponsors and Collaborators

Radboud University

Merck

Investigators

Principal Investigator:

David M. Burger, PharmD PhD

Radboud University

More Information

Additional Information:

Results published in The Journal of Clinical Pharmacology; 2009; 49; 1220 This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Dr. D.M. Burger, hospital pharmacist, Radboud University Nijmegen Medical Centre
ClinicalTrials.gov Identifier:	NCT00618241 History of Changes
Other Study ID Numbers:	UMCN-AKF 07.06
Study First Received:	February 5, 2008
Last Updated:	June 6, 2011
Health Authority:	Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Radboud University:

interactions
neuropathic pain
pharmacokinetics

Additional relevant MeSH terms:

HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases

Slow Virus Diseases
Lamotrigine
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Cardiovascular Agents
Therapeutic Uses
Anticonvulsants
Central Nervous System Agents

ClinicalTrials.gov processed this record on February 09, 2012